



# SHUKRA

PHARMACEUTICALS LTD.

September 22, 2026

To,  
BSE Limited  
Corporate Relations Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001

Scrip Code: 524632

**Sub: Submission of Corrigendum to the Postal Ballot Notice dated August 22, 2026**

Dear Sir / Madam,

Pursuant to Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Corrigendum to the Postal Ballot Notice dated August 22, 2026 ("Notice").

The Notice was previously dispatched to the shareholders on August 27, 2026, for seeking approval regarding the alteration of the Main Object Clause of the Memorandum of Association (MOA) and the change of name of the Company to "SHUKRA MEDTECH LIMITED".

This Corrigendum is being issued to substitute the original Independent Auditor's Certificate (Annexure-A) with a Revised Auditor's Certificate dated September 16, 2026, issued by the Statutory Auditors, M/s Shah Sanghvi & Associates, Chartered Accountants. This update provides detailed numerical parameters to strictly align with the layout mandated under Regulation 45 of the SEBI (LODR) Regulations, 2015, following observations from BSE Limited.

The Corrigendum is being dispatched electronically to all eligible members and is also available on the website of the Company. All other contents, details, and the active remote e-voting timelines of the original Notice remain unchanged.

We request you to kindly take the same on your records and disseminate it on your website for the information of investors.

Thanking you,

Yours faithfully,

**For Shukra Pharmaceuticals Limited**

DAKSHESH  
RAMESHCHANDRA  
SHAH

Dakshesh Shah  
Chairman & Managing Director  
DIN: 00561666



**CIN : L24231GJ1993PLC019079**

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.  
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India, Ph. : 02764-286317

Email : [info@shukrapharmaceuticals.com](mailto:info@shukrapharmaceuticals.com)

Website : [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com)



## CORRIGENDUM TO THE POSTAL BALLOT NOTICE DATED AUGUST 22, 2026

Dear Members,

This is in reference to the Postal Ballot Notice dated August 22, 2026 ("Notice"), issued by Shukra Pharmaceuticals Limited ("the Company") for seeking the approval of members via remote e-voting for:

1. Alteration of the Main Object Clause of the Memorandum of Association (MOA).
2. Change of name of the Company from "**SHUKRA PHARMACEUTICALS LIMITED**" to "**SHUKRA MEDTECH LIMITED**" and consequent amendments to the Memorandum and Articles of Association (AOA).

The Notice was dispatched to the eligible shareholders of the Company on August 27, 2026.

This Corrigendum is being issued to bring to the attention of all shareholders certain updates/revisions regarding Annexure-A (the Independent Auditor's Certificate) attached to the Explanatory Statement of the said Notice (page no. 14 to 15 of the Postal Ballot notice dated August 22, 2026).

### 1. REVISION OF THE CHARTERED ACCOUNTANT CERTIFICATE (ANNEXURE-A)

Pursuant to the observations and directions received from the BSE Limited (BSE) during the application for in-principle approval for the change of name, the Company has obtained a Revised Chartered Accountant Certificate from its Statutory Auditors, M/s Shah Sanghvi & Associates, Chartered Accountants. The original certificate required further disclosure of numerical parameters and figures to strictly align with the format under Regulation 45 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Accordingly, the existing Independent Auditor's Certificate issued by M/s Shah Sanghvi & Associates, Chartered Accountants, dated August 27, 2026 (attached as Annexure-A on Page 16–18 of the Notice), stands replaced and substituted in its entirety with the Revised Auditor's Certificate dated September 16, 2016

All references to the Chartered Accountant's Certificate under Item No. 2 of the Explanatory Statement (Page 16-18) shall be construed as references to the Auditor's Revised Certificate.

*The Revised CA Certificate has been uploaded alongside this Corrigendum and is available on the website of the Company at [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com) and on the Stock Exchange website(s).*

### 2. UPDATE ON REMOTE E-VOTING FOR SHAREHOLDERS

The remote e-voting period commenced on Friday, August 28, 2026 (09:00 A.M. IST) and concludes on Saturday, September 26, 2026 (05:00 P.M. IST).

Since the remote e-voting window is already active, it is possible that some shareholders have already cast their votes based on the previous notice layout. To ensure absolute transparency and give shareholders a fair opportunity to review the newly detailed figures in the revised certificate, the following system will apply:

**CIN : L24231GJ1993PLC019079**



# SHUKRA

## PHARMACEUTICALS LTD.

- (1) Shareholders who have already completed their e-voting prior to the issuance of this Corrigendum are permitted to log into the NSDL e-voting system and cast their vote again.
- (2) If a shareholder opts to vote again during the active voting window, their subsequent/latest electronic vote will supersede and cancel out the vote cast previously on the NSDL portal.
- (3) For shareholders who have already voted and do not wish to change their vote, their previously recorded vote will remain valid and will be counted as final by the Scrutinizer.

### 3. GENERAL INSTRUCTIONS:

This Corrigendum should be read in conjunction with the original Postal Ballot Notice dated August 22, 2026, and the Explanatory Statement annexed thereto. All other contents, terms, resolutions, and notes of the original Postal Ballot Notice remain entirely unchanged.

This Corrigendum along with the Revised CA Certificate is being sent electronically to all members whose email IDs are registered with the Depositories/RTA and is also available on the website of the Company, NSDL, BSE, and NSE.

By Order of the Board  
For Shukra Pharmaceuticals Limited

DAKSHESH  
RAMESHCHA  
NDRA SHAH

Dakshesh Shah  
Chairman & Managing Director  
DIN: 00561666

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH  
DN: c=IN, postalCode=380051, o=GUJARAT,  
street=27 JAGANNATH PARK, SURVA PARK  
ROAD, AHMEDABAD, OCTROI NAKA, 380051, s=AHMEDABAD,  
cn=Personal  
serialNumber=3ba36a25b0b9f1c2035fc09797970bc421cc9d8  
08465c129a13d99c20a2d8a,  
pseudonym=5d8b198923c743009c58888b0d069402,  
2.5.4.20=0271713632560215d15d80522da3c70d179b300215cc  
502939960337731860, email=DAKSHESH@SHUKRA.COM,  
cn=DAKSHESH RAMESHCHANDRA SHAH  
Date: 2026.09.22 10:47:06 +0530



Date: September 22, 2026  
Place: Ahmedabad

Encl: as above

**CIN : L24231GJ1993PLC019079**

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.  
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India, Ph. : 02764-286317

Email : [info@shukrapharmaceuticals.com](mailto:info@shukrapharmaceuticals.com)

Website : [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com)

**Certificate stating compliance with the sub-regulation (1) of Regulation 45 of SEBI (Listing Obligations and Disclosure Requirement), Regulation, 2015.**

**TO WHOMSOEVER IT MAY CONCERN**

We, Shah Sanghvi & Associates (Firm Registration No.: 140107W), Practicing Chartered Accountants have verified the relevant records and documents of **SHUKRA PHARMACEUTICALS LIMITED** (CIN: **L24231-GJ1993PLC019079**) having registered office at 3rd Floor, Dev House, Opp. WIAA, Judges Bungalows Road, Bodakdev, Ahmedabad, Gujarat, 380054 (herein after referred to as the company), with respect to the captioned change of name and certify that:

Based on our examination and according to the information and explanation given to us and pursuant to the requirement of provision of Regulation 45(1) and (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we do hereby confirm that

- a) a time period of at least one year has elapsed from the last name change: **The Company has not changed its name in the last one year**
- b) The condition of at least fifty percent of the total revenue in the preceding one-year period has been accounted for by the new activity suggested by the new name, as required under regulation 45 (1)(b) of the Regulation, is complied with as under:

| <b>From 01/07/2025 to 30/06/2026 (last four quarters)</b>                                        | <b>Amount (Rs. In lakhs)</b> | <b>Percentage to total income</b> |
|--------------------------------------------------------------------------------------------------|------------------------------|-----------------------------------|
| Income from prior business activity (Pharmaceuticals) -<br>From – To<br>01/07/2025 to 30/06/2026 | 7483.73                      | 100%                              |
| Income from new business activity (Medical Technology)<br>From – To<br>01/07/2025 to 30/06/2026  | 0                            | 0%                                |
| <b>Total</b>                                                                                     | <b>7483.73</b>               | <b>100.00%</b>                    |

**\*Revenue from operations has been considered while computing Income from business**



- c) the amount invested in the new activity/project is at least fifty percent of the assets of the listed entity:

**The Company has invested in procuring resources pertaining to new line of business as under:-**

| From <b>01.07.2025</b> to <b>30.06.2026</b><br>(Last four quarters)                               | Amount (Rs. In Lakhs) | Percentage to total assets |
|---------------------------------------------------------------------------------------------------|-----------------------|----------------------------|
| Investment in new business activity (Medical Technology)<br>From – To<br>01/07/2025 to 30/06/2026 | 5,058.31              | 51.04%                     |
| Investment in old business activity (Pharmaceuticals)<br>From – To<br>01/07/2025 to 30/06/2026    | 4852.18               | 48.96%                     |
| <b>Total</b>                                                                                      | <b>9,910.49</b>       | <b>100.00%</b>             |

**Note:** The detailed break-up of Investment is attached in **Annexure-1**.

**\* The Company has recommended to members for their approval for change of main object through Postal Ballot.**

This Certificate is issued at the request of the Company for submission to Stock Exchange(s), where Equity Shares of the Company are listed.

Further, certify that the Company is compliant with all the provisions/sub regulations of regulation 45 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**For, Shah Sanghvi & Associates,**

Chartered Accountants

Firm Registration No.: 140107W

Ravi Shah  
Partner

Membership no: 149091



Date: September 16, 2026


Place: Ahmedabad

UDIN: 26149091JSUYAO1032

## Annexure-1

| Sr. No.   | Particulars                          | Amount<br>(Rs. in Lakhs) |
|-----------|--------------------------------------|--------------------------|
| <b>A)</b> | <b>New Business Investment</b>       |                          |
|           | Fixed Asset                          | 1,770.71                 |
|           | Advances                             | 620.40                   |
|           | WIP/Inventories                      | 801.08                   |
|           | Investment                           | 1,047.87                 |
|           | Trade Receivable                     | 769.00                   |
|           | Cash & Cash Equivalent               | 49.25                    |
|           | <b>Total New Business Investment</b> | <b>5,058.31</b>          |
| <b>B)</b> | <b>Old Business Investment</b>       |                          |
|           | Fixed Asset                          | 1,529.19                 |
|           | WIP/Inventories                      | 1,540.47                 |
|           | Trade Receivable                     | 1,782.52                 |
|           | <b>Total Old Business Investment</b> | <b>4,852.18</b>          |

**For, Shah Sanghvi & Associates,**  
Chartered Accountants  
Firm Registration No.: 140107W

  
Ravi Shah  
Partner  
Membership no: 149091



Date: September 16, 2026  
Place: Ahmedabad  
UDIN: 26149091JSUYAO1032